(NASDAQ: MBX) Mbx Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.43%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.43%.
Mbx Biosciences's earnings in 2026 is -$86,608,000.On average, 13 Wall Street analysts forecast MBX's earnings for 2026 to be -$134,872,378, with the lowest MBX earnings forecast at -$150,198,785, and the highest MBX earnings forecast at -$115,947,598. On average, 13 Wall Street analysts forecast MBX's earnings for 2027 to be -$173,116,998, with the lowest MBX earnings forecast at -$187,048,797, and the highest MBX earnings forecast at -$149,032,645.
In 2028, MBX is forecast to generate -$189,890,370 in earnings, with the lowest earnings forecast at -$254,218,440 and the highest earnings forecast at -$80,963,409.